Boardroom chatter
What is a Deal Worth?
Benchmarking Pharma Partnering in Europe
By PAUL BRENNAN and DEREK RODGERS

When considering the costs for a European partnership there are the short-term costs related to the transaction process and the longer-term costs related to losing control of your product in the licensed territory. A company also has to consider the possibility that it might market the product itself in Europe.

Prior to performing the analysis of what is your best market entry strategy for Europe, or prior to embarking on a European partnering process, it is essential that you set expectations on potential deal size to determine if partnering is likely to be valuable to your company.

Sign-up below to gain access to the full report (PDF):

MotionHall